Form 4 for TSHA Taysha Gene Therapies, Inc.
Accepted 2023-02-06 00:00:00 ET · period of report 2023-02-02 · accession 0001209191-23-007396 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-06 | 2023-02-02 | TSHA | Alam Kamran | CFO | A - Grant | — | +18.7K | 284.8K | +7% | — |
| DM | 2023-02-06 | 2023-02-02 | TSHA | Alam Kamran | CFO | A - Grant | $0.00 | +187.3K | 149.9K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-02 | A | A | 18,691 | — | 284,812 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. 12,461 RSUs shall vest 25% on each of February 2, 2024, February 2, 2025, February 2, 2026 and February 2, 2027. The remaining RSUs, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. (F2) Each RSU represents a contingent right to receive one share the Issuer's common stock. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2023-02-02 | A | A | 37,384 | $0.00 | 37,384 | D | $1.18 · — to 2033-02-02 | 37,384 Common Stock | (F3) 24,923 shares underlying the option shall vest 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter. The remaining shares underlying the option, not subject to time vesting, shall vest upon the achievement of the closing price of the Issuer's common stock on The Nasdaq Stock Market, LLC of at least $4.00 per share on or before December 31, 2023. All vesting is subject to the Reporting Person's continuous service through each applicable vesting date. |
| 3 | Derivative | Employee Stock Option (right to buy) | 2023-02-02 | A | A | 149,900 | $0.00 | 149,900 | D | $1.18 · — to 2033-02-02 | 149,900 Common Stock | (F4) 25% of the total number of shares underlying the option shall vest and become exercisable on February 2, 2024 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. |